In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse.
The effects of the in vitro treatment with a mAb (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/lpr-lpr (MRL-lpr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-lpr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.
Nicoletti
F
F
Institute of Internal Medicine, Infectious Diseases and Immunopathology, University of Milan, Italy.
Meroni
P
P
Di Marco
R
R
Barcellini
W
W
Borghi
M O
MO
Gariglio
M
M
Mattina
A
A
Grasso
S
S
Landolfo
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000150:complications* / Q000473:pathology / Q000628:therapy; D004195:Disease Models, Animal; D005260:Female; D007371:Interferon-gamma / Q000276:immunology / Q000502:physiology*; D008180:Lupus Erythematosus, Systemic / Q000209:etiology / Q000628:therapy; D008181:Lupus Nephritis / Q000209:etiology*; D008232:Lymphoproliferative Disorders / Q000150:complications* / Q000473:pathology / Q000628:therapy; D051379:Mice
D000911:Antibodies, Monoclonal; D007371:Interferon-gamma